IRCT20260719070255N1 IRCT 2026-08-06 Tabriz University of Medical Sciences Effect of citalopram on resistant hypertension The effect of citalopram on blood pressure and quality of life in patients with resistant hypertension 2026-07-23 anticipated 60 Recruiting https://irct.ir/trial/91790 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Randomization description: Eligible patients will be randomly allocated to intervention and control groups in a 1:1 ratio using a randomization sequence generated by an artificial intelligence model (ChatGPT). The AI-generated random sequence will be produced with a fixed seed to ensure reproducibility. The allocation will be performed sequentially at the time of patient enrollment using the generated random list. 3 Resistant hypertension. Intervention 1: Intervention group: Patients in this group will receive citalopram 20 mg/day orally, added to their existing triple antihypertensive therapy. The treatment will continue for 2 months. Blood pressure will be measured at baseline, 1 month, and 2 months. Quality of life (SF-12) and psychological status (DASS-21) will be assessed at baseline and at the end of 2 months. Intervention 2: Control group: Patients in this group will continue their existing triple antihypertensive therapy alone, without any additional medication, for 2 months. Blood pressure will be measured at baseline, 1 month, and 2 months. Quality of life (SF-12) and psychological status (DASS-21) will be assessed at baseline and at the end of 2 months. No - There is not a plan to make this available Justification or reason for not sharing IPD is This is a pilot study with a small sample size (60 patients). Individual participant data (IPD) will not be shared due to the pilot nature of the study and confidentiality considerations.